Chips in Brains, AI in Biopharma and Learnings from China: Insights from ICR Healthcare’s 14th Annual Healthcare Conference
15 minutes

Chips in Brains, AI in Biopharma and Learnings from China: Insights from ICR Healthcare’s 14th Annual Healthcare Conference

Event Coverage

Reasons to Read

Discover what brain chips, AI in biopharma and China’s rise in drug innovation mean for consumer, retail and technology companies.

Read this report to discover answers to these and other questions:

  • How are brain-computer interfaces changing what is possible for patients who have lost the ability to move or speak?
  • Why do biopharma leaders expect AI to change the economics of drug discovery, and what is already happening in practice?
  • As AI spreads across biopharma, what will separate the companies that gain an advantage from the rest, and how are tech investors changing deals?
  • What do GLP-1s, sleep drugs and psychedelics suggest about consumers using medicines beyond medical need, and what does this mean for retailers and brands?
  • How has China’s role in global biopharma evolved, and what can Western companies and investors in the UK and Europe learn from it?

Companies mentioned in this report include: AstraZeneca, Blackrock Neurotech, BYD, Eli Lilly, GSK, Healx, Juvenescence, Relation Therapeutics, Trogenix.

Other relevant research:

You are currently viewing a preview of this report.

Please select an access option to view the full report. Hide Options -

Get unlimited access to all our research with one of our membership plans.

View Membership Plans
or

Contact us to purchase this report.

Contact us